Drug Update · Rare Disease

Lunsotogene parvec (Otarmeni) FDA Approves for OTOF-Associated Hearing Loss: 80% Hearing Response

September 02, 2026

Approval date

04/23/2026

Indication

Treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear [5][7].

Primary efficacy result

16/20 (80%) achieved average PTA ≤70 dB HL at Week 24 in Study DB-OTO-001 [7].

Secondary efficacy result

14/20 (70%) achieved ABR to click ≤90 dB nHL at Week 24; at Week 48, 10/12 (83%) achieved PTA ≤70 dB HL [7].

Dose (approved)

7.2 × 10^12 vector genomes (vg) in 0.24 mL per ear, single-dose intracochlear infusion [7].

Trial

Study DB-OTO-001 (NCT05788536) [7][5].

Clinical Perspective

This approval affects otolaryngologists, pediatricians, geneticists, audiologists, and advanced practice providers caring for pediatric and adult patients with molecularly confirmed biallelic OTOF variants and preserved outer hair cell function. The source-confirmed data support offering intracochlear OTARMENI to eligible patients without a prior cochlear implant in the treated ear, with dosing and administration per the approved product labeling. How durable will hearing improvement be beyond the available Week 48 data and how this translates into long-term speech and developmental outcomes remain open questions?

Dr. Lakshmi Venkatesan, MBBS, MD (Paediatrics), DM (Medical Genetics) · Medical Genetics

The FDA approved lunsotogene parvec-cwha (OTARMENI) on April 23, 2026, under accelerated approval for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene ^[2]^[3]. Approval was based on data from the single-arm Study DB-OTO-001 (NCT05788536) in which 16/20 (80%) of evaluable patients achieved an average pure tone audiometry threshold ≤70 dB HL at Week 24 ^[3]^[2].

Clinical Context

OTARMENI is a dual adeno-associated virus (AAV) vector–based intracochlear gene therapy developed by Regeneron Pharmaceuticals for OTOF gene–associated hearing loss; it is indicated for patients with preserved outer hair cell function and no prior cochlear implant in the same ear ^[1]^[3]. The BLA was reviewed under the Commissioner’s National Priority Voucher pilot program and granted accelerated approval on April 23, 2026 ^[1]^[2]. The approval letter and prescribing information identify improvement in hearing sensitivity assessed by average pure tone audiometry at Week 24 as the basis for approval; continued approval may be contingent on verification of clinical benefit in a confirmatory trial ^[2]^[3]. The product label includes dosing, intracochlear administration instructions, and perioperative prophylaxis measures described in the prescribing information ^[3].

Key Findings

Study DB-OTO-001 (single-arm; Study DB-OTO-001; NCT05788536) showed 16/20 (80%) of evaluable patients achieved the primary endpoint of average pure tone audiometry (PTA) ≤70 dB HL at Week 24 after intracochlear OTARMENI administration (primary endpoint) ^[3].
The key secondary endpoint, presence of auditory brainstem response (ABR) to a click stimulus ≤90 dB nHL at Week 24, was achieved in 14/20 (70%) of evaluable patients ^[3].
At Week 24, 9/20 (45%) achieved an average PTA ≤45 dB HL and 3/20 (15%) achieved ≤25 dB HL; by Week 48, among 12 patients evaluated, 10/12 (83%) achieved PTA ≤70 dB HL, 8/12 (67%) achieved ≤45 dB HL, and 5/12 (42%) achieved ≤25 dB HL; 9/12 (75%) demonstrated ABR ≤90 dB nHL at Week 48 ^[3].
The pivotal dataset comprised 24 treated patients (10 unilateral, 14 bilateral) with a median age of 2 years (range 10 months to 16 years); 20 patients completed efficacy assessments at 24 weeks ^[3].

Safety & Tolerability

Common adverse events explicitly reported in FDA communications included middle ear infection, nausea, dizziness, and procedural pain ^[1].
The FDA press release advised providers to monitor for surgical complications and noted that the therapy is not recommended in patients with anatomy that prevents safe access to the inner ear ^[1].

Study Design

The efficacy evidence came from an ongoing, multicenter, single-arm study (Study DB-OTO-001; NCT05788536) that enrolled pediatric patients with molecularly confirmed OTOF-associated profound sensorineural hearing loss and evidence of outer hair cell activity by otoacoustic emissions testing; 24 patients received OTARMENI and 20 completed Week 24 efficacy assessments ^[3]. The primary efficacy endpoint was achievement of hearing sensitivity threshold ≤70 dB HL by average PTA at Week 24; the key secondary endpoint was ABR to click ≤90 dB nHL at Week 24 ^[3]. The BLA was approved under accelerated approval with postmarketing requirements and commitments, including a prospective observational safety study and long-term follow-up ^[2].

FAQ

Q1 What is lunsotogene parvec (OTARMENI) approved for?

OTARMENI is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, provided there is preserved outer hair cell function and no prior cochlear implant in the same ear. This indication is approved under accelerated approval based on improvement in hearing sensitivity assessed by average PTA at Week 24 [Information was derived from FDA prescribing information and approval documents].

Q2 How does lunsotogene parvec work?

OTARMENI is an adeno-associated virus vector–based gene therapy administered by intracochlear infusion that results in expression of the OTOF gene primarily in inner hair cells, facilitating production of functional otoferlin protein and restoring synaptic transmission to the auditory nerve, as described in the clinical label and mechanism of action summary [Information was derived from FDA prescribing information].

Q3 What is the recommended dose of OTARMENI?

The recommended dose of OTARMENI for each ear is 7.2 × 10^12 vector genomes (vg) in a total volume of 0.24 mL, administered by a single-dose intracochlear infusion. Administration should be performed by a surgeon experienced in intracochlear surgery and trained in the administration procedure; bilateral administration, if applicable, should be done in a single surgical session. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects of OTARMENI?

Common adverse events reported in FDA materials included middle ear infection, nausea, dizziness, and procedural pain. The FDA communications advise providers to monitor for surgical complications and note that the therapy is not recommended in patients whose anatomy prevents safe access to the inner ear. Additional safety and long-term outcomes are being assessed through postmarketing commitments [Information was derived from FDA press announcements and prescribing information].

Clinicians should consult current prescribing information for complete dosing guidance.

Lunsotogene parvec (Otarmeni) FDA Approves for OTOF-Associated Hearing Loss: 80% Hearing Response

Direct Clinical Takeaway & Evidence Summary

Lunsotogene parvec (Otarmeni) FDA Approves for OTOF-Associated Hearing Loss: 80% Hearing Response

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Rare Disease in your inbox.

Related Clinical Updates

navepegritide (Yuviwel) FDA Approves for Achondroplasia: 1.5 cm/yr AGV Gain

FDA Approves marnetegragene autotemcel for LAD-I: 100% HSCT-free

FDA Approves Elamipretide for Barth Syndrome: 63 N Knee Strength Gain

Verified HCP Portal